IS7451A - Amínósýrur sem eru næmar fyrir alpha-2-delta prótíninu - Google Patents

Amínósýrur sem eru næmar fyrir alpha-2-delta prótíninu

Info

Publication number
IS7451A
IS7451A IS7451A IS7451A IS7451A IS 7451 A IS7451 A IS 7451A IS 7451 A IS7451 A IS 7451A IS 7451 A IS7451 A IS 7451A IS 7451 A IS7451 A IS 7451A
Authority
IS
Iceland
Prior art keywords
alpha
sensitive
amino acids
delta protein
delta
Prior art date
Application number
IS7451A
Other languages
English (en)
Inventor
Sue Barta Nancy
Bradley Schwarz Jacob
John Thorpe Andrew
Juergen Wustrow David
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28675482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7451(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of IS7451A publication Critical patent/IS7451A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
IS7451A 2002-03-28 2004-09-16 Amínósýrur sem eru næmar fyrir alpha-2-delta prótíninu IS7451A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36841302P 2002-03-28 2002-03-28
PCT/IB2003/000976 WO2003082807A2 (en) 2002-03-28 2003-03-17 Amino acids with affinity for the alpha-2-delta-protein

Publications (1)

Publication Number Publication Date
IS7451A true IS7451A (is) 2004-09-16

Family

ID=28675482

Family Applications (2)

Application Number Title Priority Date Filing Date
IS7451A IS7451A (is) 2002-03-28 2004-09-16 Amínósýrur sem eru næmar fyrir alpha-2-delta prótíninu
IS7951A IS7951A (is) 2002-03-28 2005-07-21 Amínósýrur sem eru næmar fyrir a2ð-prótíninu

Family Applications After (1)

Application Number Title Priority Date Filing Date
IS7951A IS7951A (is) 2002-03-28 2005-07-21 Amínósýrur sem eru næmar fyrir a2ð-prótíninu

Country Status (42)

Country Link
US (3) US7064147B2 (is)
EP (2) EP1614675A3 (is)
JP (2) JP3831379B2 (is)
KR (2) KR100630981B1 (is)
CN (2) CN1817854A (is)
AP (1) AP1791A (is)
AR (2) AR039154A1 (is)
AU (1) AU2003208538B2 (is)
BR (1) BR0308814A (is)
CA (1) CA2480872C (is)
CR (1) CR7501A (is)
CU (1) CU23331B7 (is)
CY (1) CY1109304T1 (is)
DE (1) DE60328469D1 (is)
DK (1) DK1492761T3 (is)
EA (2) EA008709B1 (is)
EC (1) ECSP045319A (is)
ES (1) ES2327910T3 (is)
GE (2) GEP20084298B (is)
GT (2) GT200300072AA (is)
HR (2) HRP20040891A2 (is)
IL (2) IL164110A0 (is)
IS (2) IS7451A (is)
MA (1) MA27188A1 (is)
MX (1) MXPA04009373A (is)
MY (1) MY131424A (is)
NI (1) NI200300043A (is)
NO (2) NO20044614L (is)
NZ (2) NZ535364A (is)
OA (1) OA12795A (is)
PA (1) PA8570001A1 (is)
PE (1) PE20040349A1 (is)
PL (1) PL209750B1 (is)
PT (1) PT1492761E (is)
RS (2) RS83604A (is)
SI (1) SI1492761T1 (is)
TN (1) TNSN04186A1 (is)
TW (1) TWI225864B (is)
UA (2) UA80116C2 (is)
UY (1) UY27738A1 (is)
WO (1) WO2003082807A2 (is)
ZA (1) ZA200407536B (is)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129693A1 (de) * 2001-06-22 2003-01-02 Jan Loock Verfahren zur extrakorporalen qualitativen und/oder quantitativen Erfassung neurotoxischer Substanzen im Blutplasma eines Individuums
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
BRPI0414798A (pt) 2003-09-25 2006-11-21 Warner Lambert Co métodos para usar aminoácidos com afinidade para a proteìna alfa2delta
MXPA06003395A (es) 2003-09-25 2006-06-08 Warner Lambert Co Aminoacidos con afinidad por la proteina a2d.
PT1727620E (pt) * 2004-03-12 2007-11-05 Warner Lambert Co Ligandos de biofosfina c1-simétricos e a sua utilização na síntese assimétrica da pregabalina
MXPA06014662A (es) * 2004-07-09 2007-02-12 Warner Lambert Co Preparacion de beta-amino acidos que tienen afinidad por la proteina alfa-2-delta.
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
CA2602418A1 (en) * 2005-03-24 2006-09-28 Pharmacia & Upjohn Company Llc Preparation of optically pure beta-amino acids having affinity for the alpha-2-delta protein
WO2007052134A1 (en) * 2005-11-04 2007-05-10 Pfizer Limited (2s)-2-aminomethyl-5-ethyl heptanoic acid its pharmaceutical use
CA2629896A1 (en) * 2005-11-17 2007-05-24 Pfizer Limited Isocystene derivatives for the treatment of pain
CA2640402C (en) * 2006-03-06 2012-01-03 Pfizer Products Inc. Alpha-2-delta ligands for non-restorative sleep
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
DK2710007T3 (da) 2011-05-17 2020-01-27 Principia Biopharma Inc Kinasehæmmere
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
AU2012255860C1 (en) 2011-05-17 2015-12-10 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103164756A (zh) * 2011-12-12 2013-06-19 苏州艾隆科技有限公司 贵重药品的管理方法及其系统
SMT201900344T1 (it) 2012-09-10 2019-07-11 Principia Biopharma Inc Composti di pirazolopirimidina come inibitori di chinasi
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
SG11201704808VA (en) 2014-12-18 2017-07-28 Principia Biopharma Inc Treatment of pemphigus
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
IL263815B (en) 2016-06-29 2022-07-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
AU2020365951B2 (en) 2019-10-14 2026-07-16 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
KR102993352B1 (ko) 2019-12-20 2026-07-22 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태
WO2021150723A1 (en) 2020-01-22 2021-07-29 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2025078915A1 (en) * 2023-10-12 2025-04-17 Siemens Healthcare Diagnostics Inc. Pregabalin haptens, immunogens, and protein conjugates and methods of production and use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1377736A (fr) * 1962-12-21 1964-11-06 Hoffmann La Roche Procédé pour la préparation d'acides amino-carboxyliques
FR1377366A (fr) 1963-08-19 1964-11-06 Dispositif de protection de sécurité pour appareils électriques
KR880007441A (ko) * 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
US5407960A (en) 1989-12-22 1995-04-18 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
US5614498A (en) 1990-06-07 1997-03-25 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic substance
US5011066A (en) * 1990-07-27 1991-04-30 Motorola, Inc. Enhanced collapse solder interconnection
US5239113A (en) 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
EP0561758A3 (en) 1992-03-18 1995-04-05 Monsanto Co Method of preparing optically active homo-beta-amino acids
US5578606A (en) * 1992-10-30 1996-11-26 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
WO1995014666A1 (en) 1993-11-24 1995-06-01 Merck & Co., Inc. Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
WO1995015684A1 (en) 1993-12-12 1995-06-15 Agrogene, Ltd. A novel method to protect plants from fungal infection
US5472830A (en) 1994-04-18 1995-12-05 Ocg Microelectronic Materials, Inc. Non-corrosion photoresist stripping composition
US5840961A (en) 1996-07-12 1998-11-24 G. D. Searle & Co. Asymmetric synthesis of chiral beta-amiNo acids
NZ334898A (en) * 1996-10-23 2000-09-29 Warner Lambert Co Substituted gamma aminobutyric acids as pharamceutical agents
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
GB2323594A (en) 1997-03-25 1998-09-30 Victor Martin 2-amino-alkanoic acid derivatives, 2-amino alcohols and diamines
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
US6011066A (en) 1998-02-02 2000-01-04 Veterans General Hospital-Taipei Method for treating septic shock
KR20010041905A (ko) 1998-03-16 2001-05-25 시토비아 인크. 디펩티드 카스파제 억제제 및 이의 용도
EP1013769A1 (en) 1998-12-22 2000-06-28 Dsm N.V. Process for the enzymatic preparation of amino acid derivatives with enhanced optical purity
FR2791982B1 (fr) 1999-04-06 2002-12-27 Inst Nat Sante Rech Med Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques.
CZ300834B6 (cs) * 1999-06-10 2009-08-19 Warner-Lambert Company Llc Mono- a disubstituované kyseliny 3-propyl-gamma-aminomáselné
JP2003533223A (ja) * 2000-05-16 2003-11-11 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー α２δ２カルシウムチャネルサブユニットの発現細胞株
AU2001258543A1 (en) 2000-05-17 2001-11-26 Medivir Uk Limited Branched amino acids
NZ525143A (en) 2000-09-14 2005-12-23 Gruenenthal Chemie Beta-thio-amino acids
DE10048715A1 (de) 2000-09-30 2004-05-19 Grünenthal GmbH Verwendung von Aminosäure zur Behandlung von Schmerz
CA2440834A1 (en) * 2001-03-13 2002-09-19 Queen's University At Kingston Anti-epileptogenic agents
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
CN1228312C (zh) * 2002-12-27 2005-11-23 中国科学院化学研究所 以酮为原料合成β—氨基酸的方法

Also Published As

Publication number Publication date
TW200305576A (en) 2003-11-01
AP2004003144A0 (en) 2004-09-30
EA200401127A1 (ru) 2005-06-30
RS20050667A (sr) 2007-02-05
HK1076627A1 (zh) 2006-01-20
WO2003082807A2 (en) 2003-10-09
HRP20050764A2 (en) 2006-02-28
OA12795A (en) 2006-07-18
HRP20040891A2 (en) 2004-12-31
CA2480872A1 (en) 2003-10-09
UA80018C2 (en) 2007-08-10
CU23331B7 (es) 2008-12-24
US20060154972A1 (en) 2006-07-13
MXPA04009373A (es) 2005-01-25
AP1791A (en) 2007-10-15
NZ535364A (en) 2007-05-31
ES2327910T3 (es) 2009-11-05
MY131424A (en) 2007-08-30
TNSN04186A1 (fr) 2007-03-12
PE20040349A1 (es) 2004-06-19
JP3857714B2 (ja) 2006-12-13
IL169820A0 (en) 2007-07-04
CY1109304T1 (el) 2014-07-02
KR100694719B1 (ko) 2007-03-16
IS7951A (is) 2005-07-21
CN1817854A (zh) 2006-08-16
AU2003208538B2 (en) 2009-07-16
JP2005521723A (ja) 2005-07-21
CN1653036A (zh) 2005-08-10
UA80116C2 (en) 2007-08-27
US7064147B2 (en) 2006-06-20
GT200300072A (es) 2004-01-21
NZ541320A (en) 2007-01-26
EP1492761A2 (en) 2005-01-05
CR7501A (es) 2005-01-24
KR100630981B1 (ko) 2006-10-04
US20050272783A1 (en) 2005-12-08
WO2003082807A3 (en) 2003-12-24
AU2003208538A1 (en) 2003-10-13
IL164110A0 (en) 2005-12-18
KR20040094882A (ko) 2004-11-10
JP2006028189A (ja) 2006-02-02
BR0308814A (pt) 2005-01-04
GT200300072AA (es) 2006-08-23
PA8570001A1 (es) 2003-12-10
CN100462351C (zh) 2009-02-18
US7517909B2 (en) 2009-04-14
NI200300043A (es) 2003-11-05
GEP20074123B (en) 2007-06-11
ZA200407536B (en) 2006-01-25
PT1492761E (pt) 2009-09-03
ECSP045319A (es) 2004-11-26
KR20060007446A (ko) 2006-01-24
TWI225864B (en) 2005-01-01
PL209750B1 (pl) 2011-10-31
CA2480872C (en) 2011-02-15
EP1614675A2 (en) 2006-01-11
UY27738A1 (es) 2003-10-31
DK1492761T3 (da) 2009-09-28
AR050261A2 (es) 2006-10-11
US20030195251A1 (en) 2003-10-16
JP3831379B2 (ja) 2006-10-11
EA200501497A1 (ru) 2006-06-30
MA27188A1 (fr) 2005-01-03
PL373363A1 (en) 2005-08-22
SI1492761T1 (sl) 2009-12-31
EP1492761B1 (en) 2009-07-22
NO20053918L (no) 2004-12-01
EP1614675A3 (en) 2006-03-29
EA008709B1 (ru) 2007-06-29
AR039154A1 (es) 2005-02-09
NO20044614L (no) 2004-12-01
RS83604A (sr) 2007-02-05
GEP20084298B (en) 2008-01-25
DE60328469D1 (de) 2009-09-03

Similar Documents

Publication Publication Date Title
IS7951A (is) Amínósýrur sem eru næmar fyrir a2ð-prótíninu
NO20054958D0 (no) Substitulerte aminokarboksylsyrer
DK1567112T3 (da) Thiazolidin-4-oner til at hæmme hYAK3-proteiner
DK1478328T3 (da) Bioaktive keratinpeptider
DK1663936T3 (da) Biaryloxymethylaren-carboxylsyrer
IS7668A (is) Manngerð mótefni gegn 4-1BB í mönnum
GB0226251D0 (en) Acetylated protein
DK1575379T3 (da) Ernæringssammensætninger
DE60328294D1 (de) Schreitroboter
DK1517915T3 (da) Promedikamenter af excitatoriske aminosyrer
EP1542716A4 (en) GROWTH HORMONE RELEASING PEPTIDES
DE60327407D1 (de) Immunmodulierende peptide
DK1490404T3 (da) Laktoferrin
DE60315514D1 (de) Hochdosierte ibandronat-formulierung
JP2006508095A5 (is)
IS7754A (is) Prólín afleiður með sækni fyrir kalkganga alfa-2-delta undireininguna
DK1509529T3 (da) Estere på camptotheciners position 20
AU2003215014A8 (en) Amino acids factory
DK1467750T3 (da) Orodispergerbar farmaceutisk sammensætning omfattende perindopril
IL173764A0 (en) Amino acids with affinity for the alpha2delta-protein
DE50207885D1 (de) Refraktometer
DE60319220D1 (de) Einstückige fahnenmutter
DE50302582D1 (de) Schnapp-Kugelzapfen
FI20021039A7 (fi) Kiinnitysväline
DK1625148T3 (da) Peptidkompleks